NKTR – Nektar Therapeutics
Nektar TherapeuticsNKTR
$69.06Name : Nektar Therapeutics
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $1,404,790,016.00
EPSttm : -9.83
Nektar Therapeutics
$69.06
4.12%$2.74Float Short %
16.4
Margin Of Safety %
Put/Call OI Ratio
0.44
EPS Next Q Diff
-0.72
EPS Last/This Y
0.38
EPS This/Next Y
-3.54
Price
66.43
Target Price
123.43
Analyst Recom
1
Performance Q
14.46
Relative Volume
4.72
Beta
-0.99
Ticker: NKTR
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-01-13 | NKTR | 36.61 | 0.43 | 0.67 | 24653 |
| 2026-01-14 | NKTR | 36.07 | 0.41 | 1.24 | 24408 |
| 2026-01-15 | NKTR | 35.26 | 0.42 | 1.23 | 24475 |
| 2026-01-16 | NKTR | 37.67 | 0.39 | 0.19 | 24081 |
| 2026-01-20 | NKTR | 36.2 | 0.41 | 0.59 | 21360 |
| 2026-01-21 | NKTR | 36.92 | 0.43 | 0.07 | 21425 |
| 2026-01-22 | NKTR | 36.5 | 0.43 | 0.19 | 21513 |
| 2026-01-23 | NKTR | 37.13 | 0.43 | 0.03 | 21660 |
| 2026-01-26 | NKTR | 37.25 | 0.42 | 0.50 | 21946 |
| 2026-01-27 | NKTR | 38.07 | 0.42 | 0.03 | 22001 |
| 2026-01-28 | NKTR | 35.9 | 0.42 | 0.13 | 22052 |
| 2026-01-29 | NKTR | 35.17 | 0.42 | 1.69 | 23263 |
| 2026-01-30 | NKTR | 37.44 | 0.43 | 0.05 | 23469 |
| 2026-02-02 | NKTR | 38.08 | 0.40 | 0.50 | 24611 |
| 2026-02-03 | NKTR | 38.88 | 0.42 | 0.31 | 28282 |
| 2026-02-05 | NKTR | 35.14 | 0.41 | 8.57 | 29285 |
| 2026-02-09 | NKTR | 36.93 | 0.40 | 1.18 | 29660 |
| 2026-02-10 | NKTR | 55.51 | 0.41 | 0.39 | 30094 |
| 2026-02-11 | NKTR | 66.39 | 0.44 | 0.76 | 33298 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-01-13 | NKTR | 36.67 | -28.9 | - | -8.32 |
| 2026-01-14 | NKTR | 36.06 | -28.9 | - | -8.32 |
| 2026-01-15 | NKTR | 35.33 | -28.9 | - | -8.32 |
| 2026-01-16 | NKTR | 37.58 | -28.9 | - | -8.32 |
| 2026-01-20 | NKTR | 36.26 | -28.9 | - | -8.32 |
| 2026-01-21 | NKTR | 36.89 | -28.9 | - | -8.32 |
| 2026-01-22 | NKTR | 36.53 | -28.9 | - | -8.32 |
| 2026-01-23 | NKTR | 37.13 | -46.2 | - | -8.32 |
| 2026-01-26 | NKTR | 37.26 | -28.9 | - | -8.32 |
| 2026-01-27 | NKTR | 38.01 | -28.9 | - | -8.32 |
| 2026-01-28 | NKTR | 35.98 | -28.9 | - | -8.32 |
| 2026-01-29 | NKTR | 35.18 | -28.9 | - | -8.32 |
| 2026-01-30 | NKTR | 37.33 | -28.9 | - | -8.32 |
| 2026-02-02 | NKTR | 38.06 | -28.9 | - | -8.32 |
| 2026-02-03 | NKTR | 38.85 | -28.9 | - | -8.32 |
| 2026-02-04 | NKTR | 37.60 | -28.9 | - | -8.32 |
| 2026-02-05 | NKTR | 35.14 | -28.9 | - | -8.32 |
| 2026-02-06 | NKTR | 36.77 | -28.9 | - | -8.32 |
| 2026-02-09 | NKTR | 37.03 | -28.9 | - | -8.32 |
| 2026-02-10 | NKTR | 56.04 | -28.9 | - | -8.32 |
| 2026-02-11 | NKTR | 66.43 | -28.9 | - | -8.32 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-01-13 | NKTR | -8.83 | 41.21 | 14.65 |
| 2026-01-14 | NKTR | -8.83 | 41.21 | 14.65 |
| 2026-01-15 | NKTR | -8.83 | 41.21 | 14.65 |
| 2026-01-16 | NKTR | -8.83 | 41.21 | 14.65 |
| 2026-01-20 | NKTR | -8.83 | 40.83 | 14.65 |
| 2026-01-21 | NKTR | -8.83 | 40.83 | 14.65 |
| 2026-01-22 | NKTR | -8.83 | 40.83 | 14.65 |
| 2026-01-23 | NKTR | -9.89 | 40.83 | 14.65 |
| 2026-01-26 | NKTR | -9.89 | 39.79 | 14.65 |
| 2026-01-27 | NKTR | -9.89 | 39.79 | 14.65 |
| 2026-01-28 | NKTR | -10.01 | 39.79 | 16.29 |
| 2026-01-29 | NKTR | -10.01 | 39.79 | 16.29 |
| 2026-01-30 | NKTR | -10.01 | 39.79 | 16.29 |
| 2026-02-02 | NKTR | -10.01 | 40.07 | 16.29 |
| 2026-02-03 | NKTR | -10.01 | 40.07 | 16.29 |
| 2026-02-04 | NKTR | -10.01 | 40.07 | 16.29 |
| 2026-02-05 | NKTR | -10.01 | 40.07 | 16.29 |
| 2026-02-06 | NKTR | -10.01 | 40.07 | 16.29 |
| 2026-02-09 | NKTR | -10.01 | 40.80 | 16.29 |
| 2026-02-10 | NKTR | -10.01 | 40.80 | 16.29 |
| 2026-02-11 | NKTR | -10.01 | 40.80 | 16.40 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-1.87
Avg. EPS Est. Current Quarter
-2.9
Avg. EPS Est. Next Quarter
-2.59
Insider Transactions
-10.01
Institutional Transactions
40.8
Beta
-0.99
Average Sales Estimate Current Quarter
10
Average Sales Estimate Next Quarter
10
Fair Value
Quality Score
36
Growth Score
23
Sentiment Score
81
Actual DrawDown %
83.4
Max Drawdown 5-Year %
-98.3
Target Price
123.43
P/E
Forward P/E
PEG
P/S
21.56
P/B
15.33
P/Free Cash Flow
EPS
-7.94
Average EPS Est. Cur. Y
-8.32
EPS Next Y. (Est.)
-11.86
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-192.87
Relative Volume
4.72
Return on Equity vs Sector %
-169.8
Return on Equity vs Industry %
-153.4
EPS 1 7Days Diff
-8.3
EPS 1 30Days Diff
-8.32
EBIT Estimation
Nektar TherapeuticsSector: Healthcare
Industry: Biotechnology
Employees: 61
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution processes of inflammation and has applications in a number of therapeutic indications, including acute and chronic inflammation; Tumor necrosis factor (TNF) receptor type II (TNFR2) agonist asset is a bivalent antibody molecule used to selectively stimulate TNFR2 receptor activity, without modulation of the TNFR1 signaling; and NKTR-255, an IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.
stock quote shares NKTR – Nektar Therapeutics Stock Price stock today
news today NKTR – Nektar Therapeutics stock forecast ,stock prediction 2023 2024 2025
marketwatch NKTR – Nektar Therapeutics yahoo finance google finance
stock history NKTR – Nektar Therapeutics invest stock market
stock prices NKTR premarket after hours
ticker NKTR fair value insiders trading